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Poster Session II S259values .0.9 were acceptable. Precision and mean bias\15% were
acceptable.
24 children (0.4-17.2 years) participated. Most patients (18) re-
ceived cyclosporine and methotrexate. Mean actual dose infusion
time was 1216 5.9 min. Mean AUC-all after the first cyclosporine
dose was 23976 713 hmg/L. Sufficient data were available to vali-
date the LSSs in 16 (3, 4 & 5-point LSSs) and 15 (6-point LSS) pa-
tients. Values of AUC predicted by all but the 5-point LSS were
strongly associated with AUC-all.
The 3-point LSS (2, 6 and 8 hours) is likely suitable for determin-
ing AUC following the first cyclosporine dose given as 2-hour infu-
sion to children undergoing HSCT. Further validation in a larger
number of patients is required. The relationship between acute
GVHD and cyclosporine AUC at different time periods after
HSCT merits further study.
Sample times Mean bias PrecisionAdjusted r2
(hours after start
of infusion) (%; range) (%)2, 6 and 8 0.9504 2 0.7 (213.7 to 12.4) 6.0
2, 2.5, 6 and 8 0.9547 22.7 (216.6 to 7.7) 6.0
2, 2.5, 4, 6 and 8 0.8896 24.7 (225.6 to 0.8) 9.1
2, 2.5, 4, 6, 8 and 10 0.9062 24.7 (224.2 to 20.1) 8.5274
KIDNEY INJURY (KI) IN PEDIATRIC RECIPIENTS OF ALLOGENEIC STEM
CELL TRANSPLANT (ALLOSCT): RISK OF KI IS GREATER WITH MYELOA-
BLATIVE CONDITIONING (MAC) THAN WITH REDUCED INTENSITY CON-
DITIONING (RIC) IN FIRST MONTH FOLLOWING ALLOSCT
Satwani, P.1, Bavishi, S.1, Jin, Z.2, Jacobson, J.S.3, Tallamy, B.1,
Cairo, M.S.1,4,5 1Columbia University, New York, NY; 2Columbia Uni-
versity, New York, NY; 3Columbia University, New York, NY; 4Colum-
bia University, New York, NY; 5Columbia University, New York, NY
Background:Pediatric alloSCTpatients are at substantial risk of de-
veloping KI, which contributes to transplant-related morbidity and
mortality (Holthe et al, Pediatr Nephrol., 2002).
Objective:To compare the incidence and outcomes of KI in pediat-
ric recipients following RIC vs. MAC AlloSCT in 1st year post-Al-
loSCT.
Methods: Among 170 pediatric patients, we used the Schwartz
equation to estimate creatinine clearance (eCCl) at# 2wks pre-
and 1,3,6,9 and 12 mo post-alloSCT with RIC orMAC.We catego-
rized patients whose eCCI dropped$ 50% from baseline as having
KI. Pts received Tacrolimus and MMF for GVHD prophylaxis
(Osunkwo/Cairo et al. BBMT, 2004). Other nephrotoxic exposures
included Ambisome at 3 mg/kg from day 0-100 (Roman/Cairo et al.
PBC, 2008) and CMV prophylaxis with Foscarnet/Ganciclovir
(Shereck/Cairo et al. PBC, 2007). Including risk factors significant
at 0.1 level based onc-square tests, we developedmultivariable logis-
tic regression models of predictors of kidney injury, and Cox models
of overall survival.
Results: 76 pts (median 10;0.3-22 yrs) receivedRIC-alloSCT; 94 pts
(median 8;0.3-22 yrs) receivedMA-AlloSCT. At 1 mo post alloSCT,
A total of43/94 (45.7%) MAC recipients but only 13/76 (17.1%)
RIC recipients had KI (p\0.0001). The two groups did not differ
in risk of KI at 3, 6, 9 or 12 months post-alloSCT. In univariate anal-
ysis, p-values were .0.1 for the association of KI at 1 mo with age,
sex, CMV at risk status, and fungal infections. Associations with
p-values #0.1were MAC (odds ratio {OR}-4.1, 95% CI 2.0-
8.4,p5 0.0001), poor disease risk status (OR-1.8,95% CI 0.8-4.0,
p5 0.1),VOD (OR-4.9, 95% CI 0.5-46.0, p5 0.1), and UCB
(OR-1.8,95% CI 0.9-3.6, p5 0.1). In logistic regression, only
MAC was an independent predictor of KI (OR-3.5, 95% CI 1.6-
7.7, p5 0.0001).
In the Cox model, all-cause mortality hazard ratios (HR) were:
RIC vs. MAC (HR5 0.3) p5 0.0007, poor vs. average risk disease
status (HR5 2.2) p5 0.002, UCB vs. MSD and MUD (HR-2.2)
p5 0.02, and KI vs. no KI (HR5 2.0) p5 0.006).Conclusions: In the firstmonth after alloSCT in children,MACwas
strongly associated with risk of KI, and overall, MAC and KI were
independent predictors of mortality. Avoiding KI in the first month
post-alloSCT might improve OS.275
SINGLE VS DOUBLE DOSE PALONOSETRON FOR THE PREVENTION OF
ACUTE AND DELAYED NAUSEA AND VOMITING IN PATIENTS UNDERGO-
ING HIGH DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM CELL TRANS-
PLANTATION
Marcacci, G., Becchimanzi, C., Capobianco, G., Arcamone, M.,
Corazzelli, G., Frigeri, F., Russo, F., Pinto, A. National Cancer Institute
‘‘Fondazione G. Pascale’’, Naples, Italy
Objectives:The vast majority of patients (pts) undergoing high dose
chemotherapy (HDT) and autologous stem cell transplantation
(ASCT) still experience major acute and delayed chemotherapy-in-
duced nausea and vomiting (CINV), showing how emesis control
in the ASCT setting remains sub-optimal. Palonosetron (PALO),
a new 5-hydroxytryptamine receptor antagonist with long half-life
and high receptor binding affinity, achieves a significant control of
CINV in pts receiving moderately/highly emetogenic chemother-
apy. We prospectively evaluated the efficacy of a single or double
i.v. dose PALO in pts undergoing HDT and ASCT.
Methods: A total of 60 pts (M/F5 32/28), median age 45 yrs (r16-
64), with diagnosis of lymphoma (29), myeloma (24), sarcoma (5),
acute leukemia (1), breast cancer (1) were accrued. The first cohort
(30 pts) received a single iv PALO dose (0.25 mg) plus 8 mg of dexa-
methasone (DMS) 30’ before starting of HDT while in the second
cohort (30 pts) the first dose was followed by a further PALO
(0.25 mg)/DMS (8 mg) injection 48 h after HDT. The distribution
of conditioning regimens (high-dose melphalan5 28, BEAM5 25,
MitoMel5 6, ThioEpiCTX5 1) was comparable between the two
cohorts. Acute (24 h) and delayed (120 h) CINV episodes were rated
by the visual analogic scale (MASCC/MAT) while CINV impact on
daily activities was self-assessed by pts (at 120 h from starting of
HDT), through the Functional Living Index-Emesis (FLIE) tool.
Results: No significant differences between the two groups (single
vs double PALO) emerged as to acute CINV evaluation (MAT) since
98% of pts achieved a complete response (CR5 no emesis, no need
for rescue therapy) with only 17 pts (28%) experiencing moderate
nausea (median intensity5 5, r1-10). Double-dose PALO displayed
a trend for a better control of delayed nausea which occurred in 53%
vs 77% of pts (p5 0.0581). In addition, double PALO dosing had
a highly significant impact on nausea-related modifications of daily
activities. FLIE nausea score was of a median value of 55.26
(r47.5-58.9) in pts receiving two doses of PALO vs 40.92 (r35-
45.2) for pts treated with the single PALO dosing (p5 0.0009).
Conclusion: Our results indicate that double dose PALO achieves
an optimal control of acute/delayed CINV and significantly reduces
the detrimental impact of nausea on daily activities in patients under-
going HDT. The impressive activity of PALO in the ASCT setting
might be possibly improved by combination with NK1 receptor an-
tagonists.276
END-OF-LIFE EXPERIENCE OF CHILDREN UNDERGOING STEM CELL
TRANSPLANTATION FOR MALIGNANCY: PARENT AND PROVIDER PER-
SPECTIVES AND PATTERNS OF CARE
Ullrich, C.K.1,2,3, Dussel, V.1,2,3, Hilden, J.M.3, Shaeffer, J.W.4,5,
Lehmann, L.1,3, Wolfe, J.1,2,3 1Dana-Farber Cancer Institute, Boston,
MA; 2Dana-Farber Cancer Institute, Boston, MA; 3Children’s Hospital,
Boston,MA; 4PeytonManning Children’s Hospital at St. Vincent, Indian-
apolis, IN; 5Children’s Hospitals and Clinics of Minnesota, St. Paul and
Minneapolis, MN
Background:The end-of-life (EOL) experience of childrenwho un-
dergo stem cell transplant (SCT), intensive therapy delivered with
curative intent, may differ from other children with cancer.
S260 Poster Session IIObjectives: To evaluate parent and physician perspectives and
patterns of EOL care for children after SCT.
Methods: Retrospective, cross-sectional survey of 141 parents of
children who died of cancer, and primarily received care at one of
two tertiary care pediatric institutions (response rate 64%). Chart re-
view provided additional information. Children for whom SCT was
the last cancer therapy (n5 31) were compared with those for whom
it was not (non-SCT, n5 110).
Results: The SCT group included 22/31 (71%) allogeneic and 9/
31 (29%) autologous SCT. The median (IQR) interval between last
cancer treatment and death was 65 (30-127) days (SCT group) and
25 (8-59) days (non-SCT) (p\0.001). SCT children were more
likely to die from toxicity (p\0.001). SCT parents and physicians
recognized no realistic chance for cure (RCC) later than their non-
SCT peers (Table 1) and were more likely to have a primary goal of
cure/life extension at death (parents p\0.001, physicians
p5 0.02). SCT children were more likely to die in the ICU
(p\0.001), with less opportunity for location of death to be
planned (p\0.001) or hospice to be involved (p\0.001). For
SCT children, resuscitation discussions occurred later (p\0.001)
and resulted in fewer DNR orders (p5 0.028). SCT children
were more likely to suffer highly from their last cancer therapy
(p5 0.034), and experienced more physical and psychological
symptoms (p\0.009 and \0.007, respectively). For the 13 SCT
children whose parent and physician recognized no RCC .7
days before death, intubation was less likely (p5 0.05) and resusci-
tation discussion and LOD planning more likely (both p5 0.02).
SCT parents who recognized no RCC$ 7 days before death along
with the physician, were more likely to prepare for EOL and if
their primary goal was to reduce suffering, to achieve this
(p\0.001).
Conclusion: SCT is associated with significant suffering and less
opportunity to recognize and prepare for EOL. Given the highmor-
bidity and mortality associated with SCT and the shorter time-
frames, children and families undergoing SCT may benefit from
ongoing discussions regarding prognosis, goals and opportunities
to maximize quality of life.
Parent and Physician Understanding of Prognosis: Duration of
recognition of no realistic chance for cure*
SCT (n5 31) non-SCT (n5 110) P†Parents 4 (1-822) 83.5 (29-237) \0.001
Physicians 15.5 (2-30) 84 (29-166) \0.001*Reported as median (inter-quartile range) number of days before death.
†P values correspond to logistic regression models adjusting for time
since death.277
ALTERNATE DAY MICAFUNGIN ANTI-FUNGAL PROPHYLAXIS IN PEDIAT-
RIC PATIENTS UNDERGOING HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION (HSCT): A PHARMACOKINETIC (PK) STUDY
Mehta, P.A.1, Vinks, A.2, Filipovich, A.1, Bleesing, J.1, Jodele, S.1,
Jordon, M.1, Marsh, R.1, Tarin, R.1, Edwards, S.L.1, Fearing, D.1,
Davies, S.M.1 1Cincinnati Children’s Hospital Medical Center, OH;
2Cincinnati Children’s Hospital Medical Center, OH
Disseminated fungal infection is a major cause of morbidity and
mortality in children undergoing HSCT. Prophylaxis with ampho-
tericin B can be limited by it’s renal toxicity. Oral triazoles are lim-
ited by poor absorption, large inter-individual PK variability and
hepatic toxicity, leading to breakthrough infections. Intravenous mi-
cafungin has a distinct advantage due to its better safety profile spe-
cifically in terms of hepatic and renal toxicity, and lack of drug-drug
interactions with common medications used in the HSCT setting.
We hypothesized that higher dose micafungin (3 mg/kg) every other
day will provide drug exposure similar to standard dose (1 mg/kg)
given daily, and improve patient compliance at reduced administra-tion costs. Both animal and adult patient data support the use of this
approach.
Fifteen children (M/F5 11/4, age #10 y; mean 3.9 y, range
0.6-10 y) with various hematological, metabolic and immune de-
ficiency disorders undergoing HSCT received a single dose of
Micafungin (3 mg/kg) intravenously over 1 hour. Dose selection
was based on published PK data in pediatric patients (Seibel et
al. ntimicrob Agents Chemother, 2005), and exploration of differ-
ent dosing regimens using Monte Carlo PK/PD simulation.
Blood samples were drawn around this dose (pre-dose, at the
end of infusion (1 h), and at 1.5, 2, 4, 6, 10, 24, 36 and 48 h
post dose) and PK analysis was conducted using standard non-
compartmental methods. In addition, we evaluated free AUC/
MIC (minimum inhibitory concentration) and Peak/MIC ratios
as target pharmacodynamic indices.
Micafungin at 3 mg/kg dose was well tolerated in all patients.
Measurable plasma concentrations were present in all cases at
48 hours (Table 1). Half-life and clearance observed were compara-
ble to previous pediatric PK data, with clearance being higher than
adults as expected. Volume of distribution was higher in our patients
compared to published pediatric data, likely due to a larger propor-
tion of very young children in our study cohort (\2 yrs, n5 3; 2-5
yrs, n5 9; 5-10 yrs, n5 3).
Our data show measurable plasma levels at 48 hours after
a single 3 mg/kg dose of Micafungin. After correction for pro-
tein binding, concentrations at the end of the dosing interval
during maintenance treatment will remain well above the MIC
of most common fungal pathogens. This finding suggests that
alternate day Micafungin dosing, as described here, may provide
an attractive alternative for antifungal profylaxis in HSCT
patients.
Table 1. Plasma Micafungin Pharmacokinetic Parameters
Standard
Parameters (unit) Mean Deviation (SD) RangeCmax (mg/L) 12.5 2.7 8.25 – 18.69
Cmin (mg/L at 48 hr) 0.8 0.5 0.27 – 1.99
AUC0-24 (hr*mg/L) 128.5 35.9 79.29 – 229.18
AUC0-48 (hr*mg/L) 164.4 50.7 97.46 – 305.16
AUC0-INF (hr*mg/L) 180.8 62.2 104.18 – 352.87
Cl (ml/hr/kg) 17.7 5.8 7.89 – 29.62
T 1⁄2 (h) 13.0 2.1 9.45 – 16.84
Vss (L/kg) 0.3 0.1 0.22 – 0.48Cmax - peak plasma concentration; Cmin - trough plasma concentra-
tion, AUC0-24 area under the plasma concentration-time curve at
24hrs, AUC0-48 area under the plasma concentration-time curve at
48hrs, AUC0-INF area under the plasma concentration-time curve ex-
trapolated to infinity, Cl total body clearance, T 1⁄2 elimination half-life,
Vss volume of distribution.278
DRUG INTERACTION BETWEEN ORAL CALCINEURIN INHIBITORS (TA-
CROLIMUS AND CYCLOSPORINE A) AND ORAL VORICONAZOLE IN THE
RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLAN-
TATION
Mori, T., Kato, J., Aisa, Y., Yamane, A., Ono, Y., Okamoto, S. Keio Uni-
versity School of Medicine, Tokyo, Japan
Although drug interaction between calcineurin inhibitors such as
tacrolimus and cyclosporine A (CsA) and voriconazole has long been
recognized, it has not been systemically evaluated. Based on the
limited data, a uniform dose reduction of calcineurin inhibitors on
initiating voriconazole (1/2 for CsA, 1/3 for tacrolimus) is recom-
mended. To date, the administration route (i.v. or oral) on the
drug interaction has not been the main subject of evaluation and dis-
cussion. In the present study, the drug interaction between calci-
neurin inhibitors and voriconazole were evaluated in recipients of
